MLYS
NASDAQ
$26.71
Mineralys Therapeutics Inc (MLYS)
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $49 (+83.45%)
Market Cap
$2.43B
Free Cash Flow Yield
-5.61%
Beta (5Y)
0.76
Price Chart
Valuation
Market Cap$2.43B
P/B3.77
Profitability
EBITDA-$171M
EPS-$1.85
Financial Health
Free Cash Flow Yield-5.61%
Growth & Risk
Beta (5Y)0.76
Sharpe Ratio0.95